Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.
Fiche publication
Date publication
novembre 2021
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier, Pr WESTEEL Virginie
Tous les auteurs :
Souquet PJ, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, Gervais R, Barlesi F, Pichon E, Zalcman G, Dumont P, Girard N, Poudenx M, Mazières J, Cadranel J, Debieuvre D, Dauba J, Langlais A, Morin F, Moro-Sibilot D, Westeel V, Pérol M
Lien Pubmed
Résumé
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditioned by response to cisplatin-gemcitabine (CG) with G continuation for patients with OR or switch to pemetrexed (P) for patients with SD as compared with a control arm based on the Paramount regimen.
Mots clés
Gemcitabine, Maintenance, Non-small cell lung cancer, Pemetrexed
Référence
Lung Cancer. 2021 Nov 30;164:84-90